REGENXBIO Inc. (RGNX), a clinical-stage biotechnology company pioneering AAV gene therapies, is preparing to share new interim data from its Duchenne muscular dystrophy program.
The company's lead neuromuscular asset, RGX-202, is a next-generation, one-time gene therapy designed to deliver a novel microdystrophin gene using its NAV AAV8 vector.
RGX-202 is currently being evaluated in the Phase I/II/III AFFINITY DUCHENNE trial, targeting improved muscle function in patients with Duchenne.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.